

# Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](http://FDI Lab - SciCrunch.org) on Apr 2, 2025

## Brilliant Violet 650(TM) anti-mouse CD8a

RRID:AB\_2563056

Type: Antibody

### Proper Citation

(BioLegend Cat# 100742, RRID:AB\_2563056)

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2563056](http://antibodyregistry.org/AB_2563056)

**Proper Citation:** (BioLegend Cat# 100742, RRID:AB\_2563056)

**Target Antigen:** CD8alpha

**Host Organism:** rat

**Clonality:** monoclonal

**Comments:** Applications: FC

**Antibody Name:** Brilliant Violet 650(TM) anti-mouse CD8a

**Description:** This monoclonal targets CD8alpha

**Target Organism:** mouse

**Clone ID:** Clone 53-6.7

**Antibody ID:** AB\_2563056

**Vendor:** BioLegend

**Catalog Number:** 100742

**Alternative Catalog Numbers:** 100741

**Record Creation Time:** 20231110T035218+0000

**Record Last Update:** 20240725T000058+0000

---

## Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 650(TM) anti-mouse CD8a.

No alerts have been found for Brilliant Violet 650(TM) anti-mouse CD8a.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 55 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [FDI Lab - SciCrunch.org](#).

Graham JB, et al. (2024) Unique immune profiles in collaborative cross mice linked to survival and viral clearance upon infection. *iScience*, 27(3), 109103.

Wang X, et al. (2024) Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy. *Cell reports*, 43(2), 113712.

Wang R, et al. (2024) H3K9 lactylation in malignant cells facilitates CD8+ T cell dysfunction and poor immunotherapy response. *Cell reports*, 43(9), 114686.

Zhao F, et al. (2024) GRP75-dependent mitochondria-ER contacts ensure cell survival during early mouse thymocyte development. *Developmental cell*, 59(19), 2643.

Zhou C, et al. (2024) Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. *Cancer cell*, 42(7), 1286.

Zohaib Ali M, et al. (2024) A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides. *eLife*, 13.

Textor J, et al. (2023) Machine learning analysis of the T cell receptor repertoire identifies sequence features of self-reactivity. *Cell systems*, 14(12), 1059.

Xu W, et al. (2023) GOT1 regulates CD8+ effector and memory T cell generation. *Cell reports*, 42(1), 111987.

Gelderblom M, et al. (2023) A preclinical randomized controlled multi-centre trial of anti-interleukin-17A treatment for acute ischaemic stroke. *Brain communications*, 5(2), fcad090.

Duan J, et al. (2023) Characterizing CD4 T cell differentiation in mouse small intestine using T cell transfer, lamina propria preparation, and flow cytometry. STAR protocols, 4(3), 102485.

Mahadevan KK, et al. (2023) Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells. Developmental cell, 58(17), 1562.

Lu L, et al. (2023) STING signaling promotes NK cell antitumor immunity and maintains a reservoir of TCF-1+ NK cells. Cell reports, 42(9), 113108.

Yao CC, et al. (2023) Accumulation of branched-chain amino acids reprograms glucose metabolism in CD8+ T cells with enhanced effector function and anti-tumor response. Cell reports, 42(3), 112186.

Shao TY, et al. (2023) Kruppel-like factor 2+ CD4 T cells avert microbiota-induced intestinal inflammation. Cell reports, 42(11), 113323.

Clark JT, et al. (2023) IL-18BP mediates the balance between protective and pathological immune responses to *Toxoplasma gondii*. Cell reports, 42(3), 112147.

Weeden CE, et al. (2023) Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. Cancer cell, 41(5), 837.

Wang P, et al. (2023) Adrenergic nerves regulate intestinal regeneration through IL-22 signaling from type 3 innate lymphoid cells. Cell stem cell, 30(9), 1166.

Cohen GS, et al. (2023) Transplantation elicits a clonally diverse CD8+ T cell response that is comprised of potent CD43+ effectors. Cell reports, 42(8), 112993.

Beltra JC, et al. (2023) Stat5 opposes the transcription factor Tox and rewires exhausted CD8+ T cells toward durable effector-like states during chronic antigen exposure. Immunity, 56(12), 2699.

Schädlich IS, et al. (2022) Nt5e deficiency does not affect post-stroke inflammation and lesion size in a murine ischemia/reperfusion stroke model. iScience, 25(6), 104470.